Cargando…

Ranibizumab for the treatment of wet AMD: a summary of real-world studies

Detalles Bibliográficos
Autor principal:	Chong, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108026/ https://www.ncbi.nlm.nih.gov/pubmed/27612184 http://dx.doi.org/10.1038/eye.2016.202

Ejemplares similares

Improving treatment provision of Wet AMD with intravitreal ranibizumab
por: Ghazala, Fadi, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
Publicado: (2016)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018)

Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
por: Providência, Joana, et al.
Publicado: (2018)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
por: Butt, Thomas, et al.
Publicado: (2015)

Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji, Tsuyoshi, et al.
Publicado: (2013)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen, Eric R, et al.
Publicado: (2020)

Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2020)

Epimacular brachytherapy for wet AMD: current perspectives
por: Casaroli-Marano, Ricardo P, et al.
Publicado: (2014)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta, Hemal, et al.
Publicado: (2020)

Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
por: Granstam, Elisabet, et al.
Publicado: (2021)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
por: Hatamnejad, Amin, et al.
Publicado: (2023)

Aqueous humor cytokine profiling in patients with wet AMD
por: Liu, Fang, et al.
Publicado: (2016)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Corrigendum: Efficacy of Real world Entecavir Therapy in Treatment NaïveChronic Hepatitis B Patients
Publicado: (2017)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab
por: Dikmetas, Ozlem, et al.
Publicado: (2013)

Corrigendum to ‘Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to a bilateral choroidal osteoma’ [Am. J. Ophthalmol. Case Reports (4) (2016) 7–10]
por: Zafar, Sidra, et al.
Publicado: (2017)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]
Publicado: (2016)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner, Faye, et al.
Publicado: (2019)

An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
por: Eldem, Bora, et al.
Publicado: (2018)

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
por: Callizo, Josep, et al.
Publicado: (2019)

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience [Corrigendum]
Publicado: (2014)

Expression of VEGFA‐regulating miRNAs and mortality in wet AMD
por: Blasiak, Janusz, et al.
Publicado: (2019)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
Publicado: (2017)

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
por: Varano, Monica, et al.
Publicado: (2015)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Corrigendum to “Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy”
por: Toto, Lisa, et al.
Publicado: (2020)

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China [Corrigendum]
Publicado: (2020)

Corrigendum to “Modification of systemic anti-cancer therapies and weight loss, a population-level real-world evidence study”
Publicado: (2021)

Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
por: McKibbin, M, et al.
Publicado: (2015)

Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study
por: Asahi, Masumi G, et al.
Publicado: (2020)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
Publicado: (2019)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
por: Chen, Youxin, et al.
Publicado: (2012)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum]
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3jbhvkl2q6b0sde8e5hnvsfihq